Clinical Trial Update: Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta [Phase 3]

View source ↗

Summary

Open-label extension of a Phase 3 trial evaluating denosumab in children and young adults with osteogenesis imperfecta has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteogenesis Imperfecta

Drugs mentioned

• Denosumab (denosumab)

Snippet

Sponsor: Amgen | Conditions: Osteogenesis Imperfecta (OI) | Phase 3 | Status: TERMINATED | Results posted: 2022-12-20